What Hybrid Closed Loop Systems Do and Why They Matter for Type 1 Diabetes Management

A hybrid closed loop (HCL) system is an automated insulin delivery method that combines three key components: an insulin pump, a continuous glucose monitor (CGM), and software that communicates between them. The CGM reads your glucose levels continuously, and the pump uses that data to automatically adjust how much insulin you receive throughout the day and night.

The word "hybrid" is important. Unlike a fully closed loop system, you still play an active role. You continue to make decisions about meals and monitor your diabetes, but the system handles the constant micro-adjustments of insulin delivery that would otherwise require manual intervention.

A systematic review of 28 randomized clinical trials compared seven different HCL systems (Minimed 670G, Minimed 780G, Control-IQ, CamAPS Fx, DBLG-1, DBLHU, and Omnipod 5) in people with type 1 diabetes. All HCL systems significantly increased time in target glucose range compared to traditional insulin therapy without continuous glucose monitoring.

The research found a clear hierarchy of effectiveness. The Minimed 780G achieved the highest time in target range, followed by Control-IQ, Minimed 670G, CamAPS Fx, and DBLG-1. For example, the Minimed 780G achieved 5.1 percentage points more time in target range than Control-IQ. All systems also reduced time spent with dangerously low blood sugar, with the Minimed 780G, Minimed 670G, and DBLG-1 showing the biggest improvements.

Importantly, the safety profile of HCL systems was similar to other types of insulin therapy. The risk of severe hypoglycemia (very low blood sugar) and diabetic ketoacidosis (a serious condition related to high blood sugar) did not increase with these systems.

Pregnancy creates special challenges for type 1 diabetes management. A randomized trial of 124 pregnant women with type 1 diabetes found that those using hybrid closed loop therapy spent 68% of their time in the pregnancy-specific target glucose range (63–140 mg/dL), compared to 56% in the standard care group. This 10-percentage-point difference was statistically significant. A separate trial of 91 pregnant women found similar results, with the closed-loop group achieving 65% time in target range versus 50% in standard care.

Older adults with type 1 diabetes face particular risk for severe low blood sugar, which can be especially dangerous in this age group. A randomized crossover trial of 82 adults aged 65–86 found that hybrid closed loop systems reduced the percentage of time with glucose below 70 mg/dL compared to sensor-augmented pumps. The closed-loop group spent 1.58% of their time in this dangerous range versus 2.57% in the standard pump group. Time in the safe target range (70–180 mg/dL) improved by 8.9 percentage points with HCL.

If you are newly diagnosed with type 1 diabetes—or caring for a child who is—HCL systems represent a significant advance in insulin delivery technology. They reduce the burden of constant insulin adjustments and help more people achieve better glucose control with fewer severe low blood sugar events.

Your diabetes care team can help you understand which system might fit your lifestyle and which one has the strongest evidence for your specific situation. Remember: these are tools that improve management, not cures for type 1 diabetes. Your active participation in checking in on how the system is working, managing meals and stress, and regular follow-up with your care team remains essential.

Origin: YouTube / animaT1D (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.